BPC-157
5 mg
$29.00
KPV is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (Lys-Pro-Val), supplied as a lyophilized powder vial with a separate vial of bacteriostatic water.
For research and clinical use only. Supplied to licensed practitioners and research professionals. Not evaluated by the FDA.
KPV is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (Lys-Pro-Val), supplied as a lyophilized powder vial with a separate vial of bacteriostatic water.
Supplied to licensed practitioners and research professionals only. Low molecular weight with high aqueous solubility — dose gravimetrically against net peptide content rather than gross vial weight. Store lyophilized at −20 °C. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg — $39.00 · 10 mg — $59.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 342.4 g/mol |
| CAS | 67727-97-3 |
| Sequence length | 3 |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | PEP-KPV |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
KPV is the minimal active C-terminal tripeptide (Lysine-Proline-Valine) of alpha-melanocyte-stimulating hormone (α-MSH), a natural pituitary hormone. Research groups isolated this fragment because it appears to retain anti-inflammatory activity independent of α-MSH's pigmentation and melanocortin-receptor effects.
Preclinical work, largely in rodent colitis and dermatitis models, has focused on KPV's ability to inhibit NF-κB signalling, a central pathway in inflammatory-cytokine production, without the receptor-binding profile of full-length α-MSH. This distinguishes it mechanistically from melanocortin-receptor agonists used elsewhere in research.
A recurring research application is rodent colitis models, examining local and systemic inflammatory markers after KPV administration.
Separate research lines have looked at topical application in skin-inflammation models given the peptide's origin in a hormone with dermal effects.
Because KPV appears to act downstream of the melanocortin receptors, it is used as a research tool to probe NF-κB-mediated inflammation independent of receptor-level effects.
Supplied to licensed practitioners and research professionals only. Low molecular weight with high aqueous solubility — dose gravimetrically against net peptide content rather than gross vial weight. Store lyophilized at −20 °C. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
Research suggests KPV's anti-inflammatory activity is largely independent of the melanocortin-receptor pathway that drives α-MSH's pigmentation effects, but this is an active research question, not an established clinical claim.
Further reading: for the published preclinical and clinical literature on KPV, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.